APMAdvances in Precision Medicine2424-85922424-9106Bio-Byword Scientific Publishing Pty. Ltd.10.18063/APM.v11i1.1222ArticlePromotion and Application of Weekly GLP-1 Receptor Agonist Preparations in the Treatment of Type 2 Diabetes Patientshttps://artdesignp.com/journal/APM/11/1/10.18063/APM.v11i1.1222ChenJun20261112026-01-26Objective: To explore the promotion and application of weekly GLP-1 receptor agonist in the treatment of type 2 diabetes mellitus. Methods: From December 2021 to June 2023, 100 patients with type 2 diabetes mellitus admitted to our hospital were selected and randomly divided into a control group and an experimental group, with 50 patients in each group. The control group received conventional hypoglycemic drug treatment, while the experimental group received weekly GLP-1 receptor agonist treatment. The compliance during the observation period, blood glucose control, number of hospitalizations, and patient satisfaction were compared between the two groups. Results: The compliance during the observation period in the experimental group (96.00%) was higher than that in the control group (76.00%), with a statistically significant difference (p = 0.003). After treatment, the levels of fasting plasma glucose (FPG), 2-hour postprandial blood glucose (2hPG), and glycosylated hemoglobin (HbA1c) in the experimental group were (6.11 ± 0.84) mmol/L, (8.75 ± 1.18) mmol/L, and (7.01 ± 0.16)%, respectively, which were all lower than those in the control group [(8.13 ± 1.24) mmol/L, (11.02 ± 1.76) mmol/L, and (7.64 ± 0.76)%], with statistically significant differences (all p = 0.001). After treatment, the abdominal circumference, body mass, and annual hospitalization days in the experimental group were (96.01 ± 3.84) cm, (23.02 ± 1.11) kg/m2, and (11.36 ± 2.25) days, respectively, which were all lower than those in the control group [(102.45 ± 3.41) cm, (24.54 ± 1.31) kg/m2, and (14.31 ± 5.27) days]. The drug discontinuation rate in the experimental group (4.00%) was lower than that in the control group (24.00%), with statistically significant differences (all p < 0.05). The overall satisfaction rate in the experimental group (96.00%) was higher than that in the control group (74.00%), with a statistically significant difference (p = 0.002). Conclusion: Weekly formulations of GLP-1 receptor agonists can effectively and safely lower blood glucose levels, reduce medication frequency, and offer advantages such as a low risk of hypoglycemia, weight reduction, and decreased hospitalization rates, making them worthy of widespread application.GLP-1 receptor agonist, Weekly formulation, Diabetes, Type 2

[1] Yang F, Zhu T, Yu W, 2025, Study on the Efficacy of SGLT-2 Inhibitors Combined with GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetic Nephropathy. Contemporary Medical Symposium, 23(9): 73–76. [2] Majety P, Lozada Orquera F, Edem D, et al., 2023, Pharmacological Strategies for Preventing Type 2 Diabetes Mellitus. Frontiers in Endocrinology (Lausanne), 14: 1118848. [3] Wu J, Yang K, Fan H, et al., 2023, Targeting the Gut Microbiota and Its Metabolites for the Management of Type 2 Diabetes Mellitus. Frontiers in Endocrinology (Lausanne), 14: 1114424. [4] Zhou C, Li Q, 2021, The Impact of Dulaglutide, a Once-Weekly GLP-1 Receptor Agonist, on Early Diabetic Nephropathy. Journal of Hunan Normal University (Medical Sciences), 18(6): 85–87. [5] Butler A, Eddington A, 2025, Disparities in Youth-onset Type 2 Diabetes. Endocrinology and Metabolism Clinics of North America, 54(2): 225–232. [6] Yu J, Ran S, Xu L, 2020, Application of the 8-item Morisky Medication Adherence Scale in Evaluating Medication Adherence among Elderly Patients with Chronic Diseases. Journal of Clinical Pharmacy and Therapeutics, 18(11): 63–66. [7] Chinese Medical Association, Journal Office of Chinese Medical Association, General Practice Branch of Chinese Medical Association, et al., 2019, Guidelines for Primary Care of Type 2 Diabetes Mellitus (Practice Version 2019). Chinese Journal of General Practitioners, 18(9): 810–818. [8] Jerkins T, Bell D, 2025, Stroke in the Patient with Type 2 Diabetes. Endocrine Practice, 31(4): 547–553. [9] Guzman H, Hasan L, Reid T, 2025, Treatment of Type 2 Diabetes in Patients with Obesity: A Review. Endocrinology and Metabolism Clinics of North America, 54(1): 163–173. [10] Hua Y, Wang K, Xing X, et al., 2024, Rapid Health Technology Assessment of Semaglutide Weekly Formulation Compared with Other GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes Mellitus. Drug Evaluation Research, 47(10): 2377–2387. [11] Kishi A, Fukuma S, 2023, Implementation Status of Prediction Models for Type 2 Diabetes. Primary Care Diabetes, 17(6): 655–657. [12] Li X, Li X, Wang T, et al., 2024, Effects of GLP-1 Receptor Agonists on Cognitive Function After Acute Ischemic Stroke in Patients with Type 2 Diabetes Mellitus. Journal of Capital Medical University, 45(6): 1029–1037.